Companies House 11655405 2025-12-31 2025-12-31 2025-01-01 false iso4217:GBP xbrli:pure 11655405 2024-01-01 2024-12-31 11655405 2025-12-31 11655405 2025-01-01 2025-12-31 11655405 2024-12-31 11655405 curr:PoundSterling 2025-01-01 2025-12-31 11655405 uk-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 11655405 uk-bus:FRS102 2025-01-01 2025-12-31 11655405 uk-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 11655405 uk-bus:FullAccounts 2025-01-01 2025-12-31 11655405 uk-bus:RegisteredOffice 2025-01-01 2025-12-31 11655405 uk-bus:Director1 2025-01-01 2025-12-31 11655405 uk-bus:Director2 2025-01-01 2025-12-31 11655405 uk-bus:Director3 2025-01-01 2025-12-31 11655405 uk-bus:Director4 2025-01-01 2025-12-31 11655405 uk-bus:Director5 2025-01-01 2025-12-31 11655405 uk-bus:Director6 2025-01-01 2025-12-31 11655405 uk-bus:Director7 2025-01-01 2025-12-31 11655405 uk-bus:Director8 2025-01-01 2025-12-31 11655405 uk-bus:Director9 2025-01-01 2025-12-31 11655405 uk-bus:Director10 2025-01-01 2025-12-31 11655405 uk-bus:Director11 2025-01-01 2025-12-31 11655405 uk-bus:Director12 2025-01-01 2025-12-31 11655405 uk-bus:Director13 2025-01-01 2025-12-31 11655405 uk-bus:Director14 2025-01-01 2025-12-31 11655405 uk-bus:Director15 2025-01-01 2025-12-31 11655405 uk-bus:Director16 2025-01-01 2025-12-31 11655405 uk-bus:Director17 2025-01-01 2025-12-31 11655405 uk-bus:Director18 2025-01-01 2025-12-31 11655405 uk-bus:Director19 2025-01-01 2025-12-31 11655405 uk-bus:Director20 2025-01-01 2025-12-31 11655405 uk-bus:Director21 2025-01-01 2025-12-31 11655405 uk-bus:CompanySecretary1 2025-01-01 2025-12-31 11655405 core:AfterOneYear 2025-12-31 11655405 core:AfterOneYear 2024-12-31 11655405 core:WithinOneYear 2025-12-31 11655405 core:WithinOneYear 2024-12-31 11655405 core:WithinOneYear 2025-01-01 2025-12-31 11655405 core:AfterOneYear 2025-12-31 11655405 core:AfterOneYear 2024-12-31 11655405 core:AfterOneYear 2025-01-01 2025-12-31 11655405 core:ShareCapital 2025-12-31 11655405 core:ShareCapital 2024-12-31 11655405 core:SharePremium 2025-12-31 11655405 core:SharePremium 2024-12-31 11655405 core:OtherReservesSubtotal 2025-12-31 11655405 core:OtherReservesSubtotal 2024-12-31 11655405 core:RevaluationReserve 2025-12-31 11655405 core:RevaluationReserve 2024-12-31 11655405 core:RetainedEarningsAccumulatedLosses 2025-12-31 11655405 core:RetainedEarningsAccumulatedLosses 2024-12-31 11655405 1 2025-01-01 2025-12-31 11655405 2 2025-01-01 2025-12-31 11655405 3 2025-01-01 2025-12-31 11655405 core:LandBuildings 2025-01-01 2025-12-31 11655405 core:LandBuildings 2025-12-31 11655405 core:LandBuildings 2024-01-01 2024-12-31 11655405 core:LandBuildings 2024-12-31 11655405 core:PlantMachinery 2025-01-01 2025-12-31 11655405 core:PlantMachinery 2025-12-31 11655405 core:PlantMachinery 2024-01-01 2024-12-31 11655405 core:PlantMachinery 2024-12-31 11655405 core:FurnitureFittingsToolsEquipment 2025-01-01 2025-12-31 11655405 core:FurnitureFittingsToolsEquipment 2025-12-31 11655405 core:FurnitureFittingsToolsEquipment 2024-01-01 2024-12-31 11655405 core:FurnitureFittingsToolsEquipment 2024-12-31 11655405 core:OfficeEquipment 2025-01-01 2025-12-31 11655405 core:OfficeEquipment 2025-12-31 11655405 core:OfficeEquipment 2024-01-01 2024-12-31 11655405 core:OfficeEquipment 2024-12-31 11655405 core:Vehicles 2025-01-01 2025-12-31 11655405 core:Vehicles 2025-12-31 11655405 core:Vehicles 2024-01-01 2024-12-31 11655405 core:Vehicles 2024-12-31 11655405 core:NetGoodwill 2025-01-01 2025-12-31 11655405 core:NetGoodwill 2025-12-31 11655405 core:NetGoodwill 2024-01-01 2024-12-31 11655405 core:NetGoodwill 2024-12-31 11655405 core:IntangibleAssetsOtherThanGoodwill 2025-01-01 2025-12-31 11655405 core:IntangibleAssetsOtherThanGoodwill 2025-12-31 11655405 core:IntangibleAssetsOtherThanGoodwill 2024-01-01 2024-12-31 11655405 core:IntangibleAssetsOtherThanGoodwill 2024-12-31

# VACCITECH ONCOLOGY LIMITED

## Company Registration Number:
11655405 (England and Wales)

## Unaudited statutory accounts for the year ended 31 December 2025

## Period of accounts

## Start date: 1 January 2025

## End date: 31 December 2025

# VACCITECH ONCOLOGY LIMITED

## Contents of the Financial Statements

for the Period Ended 31 December 2025

Directors report |
Profit and loss |
Balance sheet |
Additional notes |
Balance sheet notes |

# VACCITECH ONCOLOGY LIMITED

Directors' report period ended 31 December 2025

The directors present their report with the financial statements of the company for the period ended 31 December 2025

Political and charitable donations

No political contributions were made by the Company in the year ended 31 December 2025 (2024: Nil).

Directors

The directors shown below have held office during the whole of the period from
1 January 2025 to 31 December 2025

W.J.Enright
A.Hammacher

The director shown below has held office during the period of
1 January 2025 to 23 November 2025

J.C.A.Skipper

The director shown below has held office during the period of
23 November 2025 to 31 December 2025

P.R.Olsson

Secretary Oakwood Corporate Secretary Limited

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
27 March 2026

And signed on behalf of the board by:
Name: W.J.Enright
Status: Director

# VACCITECH ONCOLOGY LIMITED

## Profit And Loss Account

for the Period Ended 31 December 2025

| 2025 | 2024
--- | --- | ---
| £ | £
Cost of sales: | ( 49,000 ) | ( 347,000 )
Gross profit(or loss): | (49,000) | (347,000)
Administrative expenses: | ( 47,000 ) | ( 76,000 )
Operating profit(or loss): | (96,000) | (423,000)
Interest receivable and similar income: |  | 6,000
Profit(or loss) before tax: | (96,000) | (417,000)
Tax: | ( 2,000 ) | 21,000
Profit(or loss) for the financial year: | (98,000) | (396,000)

# VACCITECH ONCOLOGY LIMITED

## Balance sheet

As at 31 December 2025

| Notes | 2025 | 2024
--- | --- | --- | ---
|  | £ | £
Current assets
Debtors: | 3 | 5,000 | 153,000
Cash at bank and in hand: |  | 342,000 | 983,000
Total current assets: |  | 347,000 | 1,136,000
Creditors: amounts falling due within one year: | 4 | ( 88,000 ) | ( 779,000 )
Net current assets (liabilities): |  | 259,000 | 357,000
Total assets less current liabilities: |  | 259,000 | 357,000
Total net assets (liabilities): |  | 259,000 | 357,000
Capital and reserves
Called up share capital: |  | 1,000 | 1,000
Share premium account: |  | 5,443,000 | 5,443,000
Profit and loss account: |  | (5,185,000 ) | (5,087,000 )
Total Shareholders' funds: |  | 259,000 | 357,000

The notes form part of these financial statements

# VACCITECH ONCOLOGY LIMITED

## Balance sheet statements

For the year ending 31 December 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 27 March 2026
and signed on behalf of the board by:

Name: W.J.Enright
Status: Director

The notes form part of these financial statements

# VACCITECH ONCOLOGY LIMITED

## Notes to the Financial Statements

for the Period Ended 31 December 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

# VACCITECH ONCOLOGY LIMITED

## Notes to the Financial Statements

for the Period Ended 31 December 2025

- ## 2. Employees

  | 2025 | 2024
  --- | --- | ---
  Average number of employees during the period | 0 | 0

# VACCITECH ONCOLOGY LIMITED

## Notes to the Financial Statements

for the Period Ended 31 December 2025

## 3. Debtors

| 2025 | 2024
--- | --- | ---
| £ | £
Trade debtors | 3,000 | 0
Prepayments and accrued income | 0 | 80,000
Other debtors | 2,000 | 73,000
Total | 5,000 | 153,000

Included in other debtors for 2024 is £69k of tax recoverable

# VACCITECH ONCOLOGY LIMITED

## Notes to the Financial Statements

for the Period Ended 31 December 2025

## 4. Creditors: amounts falling due within one year note

| 2025 | 2024
--- | --- | ---
| £ | £
Trade creditors |  | 10,000
Accruals and deferred income | 34,000 | 56,000
Other creditors | 54,000 | 713,000
Total | 88,000 | 779,000

Other creditors relate to amounts owed to group undertakings